Literature DB >> 11257348

Clinical relevance of lower Hib response in DTPa-based combination vaccines.

J Poolman1, A Kaufhold, D De Grave, D Goldblatt.   

Abstract

Combination vaccines are essential to enable administration of all the required antigens in routine infant immunisation schedules at any single visit. Some combinations of diphtheria-tetanus-acellular pertussis (DTPa) with Haemophilus influenzae type b (Hib) conjugate vaccines have been shown to result in lower Hib titres than when Hib is administered separately. While confirming that a primary series with a DTPa-HBV-IPV/Hib combination gives lower antibody levels than separate Hib conjugates, we show that the nature (isotype and IgG subclasses) and function (avidity and opsonic activity) of the antibodies are the same, and immunologic memory is induced. It is likely therefore that the DTPa-HBV-IPV/Hib combination will be efficacious against Hib disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257348     DOI: 10.1016/s0264-410x(00)00517-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Effect of a fourth Haemophilus influenzae type b immunisation in preterm infants who received dexamethasone for chronic lung disease.

Authors:  P Clarke; P J Powell; D Goldblatt; M J Robinson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

2.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

3.  Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.

Authors:  J McVernon; M E Ramsay; A R McLean
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

4.  Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Clayton Harro; Ligia A Pinto
Journal:  Vaccine       Date:  2010-06-17       Impact factor: 3.641

5.  Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.

Authors:  Raïssa Nadège Caboré; Kirsten Maertens; Alexandre Dobly; Elke Leuridan; Pierre Van Damme; Kris Huygen
Journal:  Virulence       Date:  2017-02-22       Impact factor: 5.882

6.  Immunoglobulin G avidities in infants in Mexico after primary immunization with three doses of polyribosylribitol phosphate-tetanus toxoid Haemophilus influenzae type b vaccine.

Authors:  Patricia Gómez-de-León; F Javier Díaz-García; Alberto Villaseñor-Sierra; Jorge Segura; Martha I Carranza; José Luis Arredondo-Garcia; José Ignacio Santos
Journal:  Clin Vaccine Immunol       Date:  2008-04-16

7.  Immunogenicity and Reactogenicity following Primary Immunisation with a Combined DTaP-HBV Vaccine and a Haemophilus influenzae Type B Vaccine Administered by Separate or Mixed Injection.

Authors:  G Gabutti; G Bona; P Dentico; F Bamfi; K Hardt; S Majori; P Crovari
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

8.  Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

Authors:  Philippe A Denoël; David Goldblatt; Isabel de Vleeschauwer; Jeanne-Marie Jacquet; Michael E Pichichero; Jan T Poolman
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

Review 9.  DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

Authors:  Monique P Curran; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Haemophilus influenzae type b reemergence after combination immunization.

Authors:  Nik G Johnson; Jens U Ruggeberg; Gail F Balfour; Y Chen Lee; Helen Liddy; Diane Irving; Joanna Sheldon; Mary P E Slack; Andrew J Pollard; Paul T Heath
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.